[1] Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 4-17.
[2] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease[J]. Cell Res, 2020, 30(6): 492-506.
[3] Hsu C L, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nature Reviews. Microbiology, 2023, 21(11): 719-733.
[4] Takeuchi T, Nakanishi Y, Ohno H. Microbial Metabolites and Gut Immunology[J]. Ann Rev Immunol, 2024, 42(1): 153-178.
[5] Carbone M, Neuberger J M. Autoimmune liver disease, autoimmunity and liver transplantation[J]. J Hepatol, 2014, 60(1): 210-223.
[6] Lin R, Zhou L, Zhang J, et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J]. Int J Clin Exp Pathol, 2015, 8(5): 5153-5160.
[7] Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161.
[8] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577.
[9] Liwinski T, Casar C, Ruehlemann M C, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1417-1428.
[10] Elsherbiny N M, Rammadan M, Hassan E A, et al. Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients[J]. Microorganisms, 2020, 8(7): 1011.
[11] Lou J, Jiang Y, Rao B, et al. Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals[J]. Front Cell Infect Microbiol, 2020, 10: 342.
[12] Smyk D S, Bogdanos D P, Kriese S, et al. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside[J]. Clin Res Hepatol Gastroenterol, 2012, 36(2): 110-121.
[13] Lv LX, Fang DQ, Shi D, et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis[J]. Environ Microbiol, 2016,18(7):2272-2286.
[14] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541.
[15] Chen W, Wei Y, Xiong A, et al. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38.
[16] Loomba R, Ling L, Dinh D M, et al. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH[J]. Hepatology, 2021, 73(1): 126-143.
[17] Li B, Zhang J, Chen Y, et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis[J]. Gut Microbes, 2021, 13(1): 1946366.
[18] Kitahata S, Yamamoto Y, Yoshida O, et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis[J]. Sci Rep,2021,11(1):19705.
[19] Cortez R V, Moreira L N, Padilha M, et al. Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis[J]. Front Immunol, 2020, 11: 598152.
[20] Iwasawa K, Suda W, Tsunoda T, et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis[J]. Gut, 2017, 66(7): 1344-1346.
[21] Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65(10): 1681-1689.
[22] Kummen M, Holm K, Anmarkrud J A, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J]. Gut, 2017, 66(4): 611-619.
[23] Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis[J]. Nat Microbiol, 2019, 4(3): 492-503.
[24] van den Bogert B, Meijerink M, Zoetendal E G, et al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota[J]. PloS One, 2014, 9(12): e114277.
[25] Rühlemann M, Liwinski T, Heinsen F A, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis[J]. Aliment Pharmacol Ther, 2019, 50(5): 580-589.
[26] Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis[J]. World J Gastroenterol, 2017, 23(25): 4548-4558.
[27] Quraishi M N, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD[J]. Gut, 2017, 66(2): 386-388.
[28] Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2020, 69(4): 665-672.
[29] Kummen M, Thingholm L B, Rühlemann M C, et al. Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis[J]. Gastroenterology, 2021, 160(5): 1784-1798.e0.
[30] Hole M J, Jørgensen K K, Holm K, et al. A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation[J]. Hepatology , 2023, 77(3): 715-728.
[31] Liu Q, Li B, Li Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut, 2022, 71(5): 899-909.
[32] Lemoinne S, Kemgang A, Ben Belkacem K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis[J]. Gut, 2020, 69(1): 92-102.
[33] Rühlemann M C, Solovjeva M E L, Zenouzi R, et al. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species[J]. Gut, 2020, 69(10): 1890-1892.
[34] Christen U, Hintermann E. Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?[J]. Front Immunol, 2018, 9: 163.
[35] Abe K, Takahashi A, Fujita M, et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease[J]. PloS One, 2018, 13(7): e0198757.
[36] Lapidot Y, Amir A, Ben-Simon S, et al. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(1): 191-201.
[37] Iwasawa K, Suda W, Tsunoda T, et al. Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker[J]. Sci Rep, 2018, 8(1): 5480.
[38] Katt J, Schwinge D, Schoknecht T, et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis[J]. Hepatology, 2013, 58(3): 1084-1093.
[39] Leinwand J C, Paul B, Chen R, et al. Intrahepatic microbes govern liver immunity by programming NKT cells[J]. J Clin Invest, 2022, 132(8): e151725. |
